Pfizer Inc
NYSE:PFE

Watchlist Manager
Pfizer Inc Logo
Pfizer Inc
NYSE:PFE
Watchlist
Price: 26.71 USD 1.33% Market Closed
Market Cap: 151.4B USD
Have any thoughts about
Pfizer Inc?
Write Note

Wall Street
Price Targets

PFE Price Targets Summary
Pfizer Inc

Wall Street analysts forecast PFE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PFE is 32.22 USD with a low forecast of 25.25 USD and a high forecast of 47.25 USD.

Lowest
Price Target
25.25 USD
5% Downside
Average
Price Target
32.22 USD
21% Upside
Highest
Price Target
47.25 USD
77% Upside

PFE Last Price Targets
Pfizer Inc

The latest public price target was made on Oct 30, 2024 by Chris Shibutani from Goldman Sachs , who expects PFE stock to rise by 24% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Chris Shibutani
Goldman Sachs
33 USD
Upside 24%
1 month ago
Oct 30, 2024
Pfizer (PFE) PT Raised to $33 at Goldman Sachs
StreetInsider
Courtney Breen
Bernstein
32 USD
Upside 20%
2 months ago
Oct 17, 2024
Pfizer initiated with a Market Perform at Bernstein
TheFly
Carter Gould
Barclays
32 USD
Upside 20%
2 months ago
Sep 25, 2024
Pfizer withdrawal raises business development questions, says Barclays
TheFly
Narumi Nakagiri
Daiwa
34 USD
Upside 27%
4 months ago
Aug 7, 2024
Daiwa Securities Upgrades Pfizer (PFE) to Outperform (2)
StreetInsider
Mohit Bansal
Wells Fargo
30 USD
Upside 12%
4 months ago
Jul 31, 2024
Pfizer price target raised to $30 from $28 at Wells Fargo
TheFly
Chris Shibutani
Goldman Sachs
34 USD
Upside 27%
4 months ago
Jul 31, 2024
Pfizer (PFE) PT Raised to $34 at Goldman Sachs
StreetInsider
Vamil Divan
Guggenheim
36 USD
Upside 35%
4 months ago
Jul 30, 2024
Pfizer Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Benzinga
Carter Gould
Barclays
30 USD
Upside 12%
5 months ago
Jul 10, 2024
Pfizer price target raised to $30 from $28 at Barclays
TheFly
Evan Seigerman
BMO Capital
36 USD
Upside 35%
7 months ago
May 22, 2024
Pfizer cost reduction program a positive for the shares, says BMO
TheFly
Louise Chen
Cantor Fitzgerald
45 USD
Upside 68%
10 months ago
Feb 14, 2024
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
Benzinga
Thomas Yeh
Morgan Stanley
20 USD
Downside 25%
1 year ago
Dec 14, 2023
Harmonic To Rally Over 80%? Here Are 10 Top Analyst Forecasts For Thursday
Benzinga
Terence Flynn
Morgan Stanley
37 USD
Upside 39%
1 year ago
Nov 27, 2023
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields
Benzinga
Unknown Analyst
Morgan Stanley
45 USD
Upside 68%
1 year ago
Feb 1, 2023
Morgan Stanley Maintains Equal-Weight on Pfizer, Lowers Price Target to $45
Benzinga
Unknown Analyst
Atlantic Equities
46 USD
Upside 72%
1 year ago
Feb 1, 2023
Atlantic Equities Maintains Neutral on Pfizer, Lowers Price Target to $46
Benzinga
Unknown Analyst
Leerink Partners
48 USD
Upside 80%
1 year ago
Feb 1, 2023
SVB Leerink Maintains Market Perform on Pfizer, Lowers Price Target to $48
Benzinga
Unknown Analyst
Credit Suisse
50 USD
Upside 87%
1 year ago
Feb 1, 2023
Credit Suisse Maintains Outperform on Pfizer, Lowers Price Target to $50
Benzinga
Unknown Analyst
Barclays
44 USD
Upside 65%
1 year ago
Feb 1, 2023
Barclays Maintains Equal-Weight on Pfizer, Lowers Price Target to $44
Benzinga
Show More Price Targets
Show Less Price Targets
Chris Shibutani
Goldman Sachs
Price Target 33 USD
Upside/Downside 24%
View Source
Courtney Breen
Bernstein
Price Target 32 USD
Upside/Downside 20%
View Source
Carter Gould
Barclays
Price Target 32 USD
Upside/Downside 20%
View Source
Narumi Nakagiri
Daiwa
Price Target 34 USD
Upside/Downside 27%
View Source
Mohit Bansal
Wells Fargo
Price Target 30 USD
Upside/Downside 12%
View Source
Chris Shibutani
Goldman Sachs
Price Target 34 USD
Upside/Downside 27%
View Source
Vamil Divan
Guggenheim
Price Target 36 USD
Upside/Downside 35%
View Source
Carter Gould
Barclays
Price Target 30 USD
Upside/Downside 12%
View Source
Evan Seigerman
BMO Capital
Price Target 36 USD
Upside/Downside 35%
View Source
Louise Chen
Cantor Fitzgerald
Price Target 45 USD
Upside/Downside 68%
View Source
Thomas Yeh
Morgan Stanley
Price Target 20 USD
Upside/Downside 25%
View Source
Terence Flynn
Morgan Stanley
Price Target 37 USD
Upside/Downside 39%
View Source
Unknown Analyst
Morgan Stanley
Price Target 45 USD
Upside/Downside 68%
View Source
Unknown Analyst
Atlantic Equities
Price Target 46 USD
Upside/Downside 72%
View Source
Unknown Analyst
Leerink Partners
Price Target 48 USD
Upside/Downside 80%
View Source
Unknown Analyst
Credit Suisse
Price Target 50 USD
Upside/Downside 87%
View Source
Unknown Analyst
Barclays
Price Target 44 USD
Upside/Downside 65%
View Source
Show More Price Targets
Show Less Price Targets
Pfizer Inc Competitors:
Price Targets
ORCHPHARMA
Orchid Pharma Ltd
5% Downside
4530
Hisamitsu Pharmaceutical Co Inc
12% Upside
293480
Hana Pharm Co Ltd
65% Upside
688321
Shenzhen Chipscreen Biosciences Co Ltd
98% Upside
4887
Sawai Group Holdings Co Ltd
10% Upside
688185
CanSino Biologics Inc
10% Upside
SBBC
Simply Better Brands Corp
75% Upside

Revenue
Forecast

Revenue Estimate
Pfizer Inc

For the last 8 years the compound annual growth rate for Pfizer Inc's revenue is 2%. The projected CAGR for the next 4 years is 2%.

2%
Past Growth
2%
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Pfizer Inc

For the last 8 years the compound annual growth rate for Pfizer Inc's operating income is -1%. The projected CAGR for the next 4 years is 14%.

-1%
Past Growth
14%
Estimated Growth
Estimates Accuracy
-22%
Average Miss

Net Income
Forecast

Net Income Estimate
Pfizer Inc

For the last 8 years the compound annual growth rate for Pfizer Inc's net income is -14%. The projected CAGR for the next 4 years is 70%.

-14%
Past Growth
70%
Estimated Growth
Estimates Accuracy
-35%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is PFE's stock price target?
Price Target
32.22 USD

According to Wall Street analysts, the average 1-year price target for PFE is 32.22 USD with a low forecast of 25.25 USD and a high forecast of 47.25 USD.

What is Pfizer Inc's Revenue forecast?
Projected CAGR
2%

For the last 8 years the compound annual growth rate for Pfizer Inc's revenue is 2%. The projected CAGR for the next 4 years is 2%.

What is Pfizer Inc's Operating Income forecast?
Projected CAGR
14%

For the last 8 years the compound annual growth rate for Pfizer Inc's operating income is -1%. The projected CAGR for the next 4 years is 14%.

What is Pfizer Inc's Net Income forecast?
Projected CAGR
70%

For the last 8 years the compound annual growth rate for Pfizer Inc's net income is -14%. The projected CAGR for the next 4 years is 70%.

Back to Top